NCNA - NuCana plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.67
-1.71 (-8.82%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close19.38
Open19.21
Bid18.08 x 900
Ask18.71 x 800
Day's Range17.67 - 19.21
52 Week Range9.32 - 32.00
Volume15,689
Avg. Volume49,143
Market Cap559.878M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.17
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2,962.92
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    NuCana to Participate in the 2018 Evercore ISI HealthCONx Conference

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the 2018 Evercore ISI HealthCONx Conference in Boston, MA on Tuesday, November 27, 2018. NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.

  • GlobeNewswire14 days ago

    NuCana to Participate in the Jefferies 2018 London Healthcare Conference

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2018 London Healthcare Conference in London, UK. The presentation will be webcast live and available for replay under “Events & Presentations” in the Investors section of the Company's website at www.nucana.com. NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.

  • GlobeNewswire20 days ago

    NuCana Announces First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer

    This study is evaluating NUC-3373 in combination with other agents typically administered with 5-fluorouracil (5-FU) in patients with advanced colorectal cancer. NUC-3373 is NuCana’s ProTide transformation of the active anti-cancer metabolite of 5-FU.

  • NuCana Sees Hammer Chart Pattern: Time to Buy?
    Zacks28 days ago

    NuCana Sees Hammer Chart Pattern: Time to Buy?

    NuCana PLC has been struggling lately, but the selling pressure may be coming to an end soon.

  • GlobeNewswirelast month

    NuCana Presents Data from Phase I Study of NUC-3373 at ESMO 2018

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today the presentation of additional data from a Phase I clinical study of NUC-3373, its ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU), in patients with advanced solid tumors, at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany. To date, 36 patients, all with metastatic cancer, have been enrolled in the study, with 29 patients receiving NUC-3373 on a weekly schedule on days one, eight, 15 and 22 of a 28-day cycle at doses ranging from 125mg/m2 to 1,500mg/m2 and seven patients receiving NUC-3373 on an alternate-week, or fortnightly, schedule on days one and 15 of a 28-day cycle at doses ranging from 1,500mg/m2 to 1,875mg/m2.

  • GlobeNewswirelast month

    NuCana Reports Additional Promising Clinical Data on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer at ESMO 2018

    50% Objective Response Rate on Intent-to-Treat Basis Observed Phase III Study of Acelarin in Front-Line Advanced Biliary Tract Cancer Planned EDINBURGH, United Kingdom, Oct..

  • GlobeNewswirelast month

    NuCana to Present New Data from its ProTide Portfolio at the European Society for Medical Oncology (ESMO) 2018 Congress

    EDINBURGH, United Kingdom, Oct. 09, 2018 -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for.

  • GlobeNewswire3 months ago

    NuCana to Participate in Citi’s 13th Annual Biotech Conference

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at Citi’s 13th Annual Biotech Conference in Boston on September 5th and 6th, 2018. NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.

  • GlobeNewswire3 months ago

    NuCana Reports Second Quarter 2018 Financial Results and Provides Business Update

    EDINBURGH, United Kingdom, Aug. 28, 2018-- NuCana plc announced financial results for the second quarter ended June 30, 2018 and provided an update on its extensive clinical program with its transformative ...

  • Better Know Biotech: 2 Stocks You've Got to Know About
    Motley Fool6 months ago

    Better Know Biotech: 2 Stocks You've Got to Know About

    These two small-cap biotech stocks could be about to make it big.

  • GlobeNewswire6 months ago

    NuCana Reports First Quarter 2018 Financial Results

    EDINBURGH, United Kingdom, May  23, 2018  (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, ...

  • GlobeNewswire6 months ago

    NuCana Announces Appointment of Cyrille Leperlier to its Board of Directors

    NuCana plc (NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients, announced the appointment of Dr. Cyrille Leperlier to its Board as an independent non-executive Director.  NuCana`s ProTide(TM) technology transforms some of the most widely prescribed chemotherapy agents into more effective and safer medicines. Dr. Leperlier brings to NuCana over 30 years of experience in the pharmaceutical and biotechnology industry.  Most recently, Dr. Leperlier served as Senior Scientific Advisor for Sanofi`s Corporate Business Development and M&A Group, where, among other transactions, he was deeply involved in Sanofi`s acquisition of Genzyme.  Prior to this role, Dr. Leperlier served as Medical Director in Japan for Sanofi.  Before joining Sanofi, Dr. Leperlier was Medical Director and Global Head of Clinical Development at Rhone Poulenc Rorer and previously worked for Takeda in a variety of operational and medical affairs roles.  Dr. Leperlier received an M.D. from the University of Paris, Saint-Antoine School of Medicine and a Master in Human Biology (major in physiology) from the Medical University of Paris.

  • GlobeNewswire7 months ago

    NuCana plc Announces Appointment of Adam George to its Board of Directors

    EDINBURGH, United Kingdom, April 09, 2018 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients ...

  • GlobeNewswire8 months ago

    NuCana Reports Financial Results for the Year Ended December 31, 2017

    EDINBURGH, United Kingdom, March 21, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the year ended December 31, 2017 and provided an update on its extensive clinical ...

  • GlobeNewswire9 months ago

    NuCana plc to Participate in the Cowen and Company 38th Annual Health Care Conference

    EDINBURGH, United Kingdom, March 02, 2018 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients ...

  • ACCESSWIRE10 months ago

    Wired News – NuCana Announced Positive Results from Clinical Data on Acelarin® as Front-Line Treatment of Advanced Biliary Tract Cancer at ASCO GI 2018

    LONDON, UK / ACCESSWIRE / January 23, 2018 / Active-Investors.com has just released a free research report on NuCana PLC (NASDAQ: NCNA ). If you want access to this report all you need to do is sign up ...

  • Market Exclusive10 months ago

    Here’s What’s Moving NuCana plc (NASDAQ:NCNA) and PHARMA MAR (OTCMKTS:PHMMF)

    NuCana plc (NASDAQ:NCNA) and PHARMA MAR (OTCMOTH:PHMMF) are two big biotech movers heading into the start of a fresh week in the space, with both companies attracting volume based on the release of fresh data. Here is a look at the data from each and what it means for developing programs of the companies going […] The post Here’s What’s Moving NuCana plc (NASDAQ:NCNA) and PHARMA MAR (OTCMKTS:PHMMF) appeared first on Market Exclusive.

  • GlobeNewswire10 months ago

    NuCana Announces Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer

    NuCana Planning to Initiate a Phase 3 Study of Acelarin in Front-Line Advanced Biliary Tract Cancer EDINBURGH, United Kingdom, January 19, 2018 (GLOBE NEWSWIRE) - NuCana plc (NASDAQ: NCNA) announced interim ...